Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5%.
Subscribe to our email newsletter
Moxifloxacin Hydrochloride Ophthalmic Solution USP, 0.5% is a generic version of Alcon Pharmaceuticals’ Vigamox, an antibiotic solution that is indicated for the treatment of bacterial conjunctivitis.
Alcon Pharmaceuticals and Alcon Research filed suit against Watson on 7 April 2011 in the US District Court for the District of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent Nos. 6,716,830 and 7,671,070.
Alcon’s lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson’s ANDA until 1 September 2013, or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.